During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
A cloudy start in the east with the odd spot of drizzle, but brightening up here through the morning.
Charlie Gard's parents are spending their "last precious moments" with the terminally ill boy after a legal fight over his treatment ended.
Leaseholds on new-build houses could be banned outright under proposals to stamp out abuses of the system.